Abilify package insert pdf
Rating: 4.4 / 5 (4987 votes)
Downloads: 32789

CLICK HERE TO DOWNLOAD

Maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see CLINICAL STUDIES ]Bipolar I Disorder ABILIFY (aripiprazole) is not approved for the treatment of patients with dementia-related psychosis [see WARNINGS AND PRECAUTIONS ()]. Initial U.S. ApprovalWARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS and ABILIFY is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced ABILIFY®(aripiprazole) Injection for Intramuscular Use is a clear, colorless solution available as a ready-to-use, mg/ mL (mg/mL) solution in clear, Typeglass ABILIFY MAINTENA is only to be administered by intramuscular injection by a healthcare professional. Remove the ABILIFY ASIMTUFII pre-filled syringe from the package. The dose should be increased tomg/day, with subsequent increases toormg/day if needed. Bipolar I Disorder Treatment Information For Patients ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension, for intramuscular use Initial U.S. ApprovalWARNING: INCREASED MORTALITY IN File Size: KB ABILIFY ASIMTUFII is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults (1) as maintenance monotherapy treatment of bipolar I disorder in ABILIFY Injection is indicated for the treatment of: Agitation associated with schizophrenia or bipolar maniaDOSAGE AND ADMINISTRATION ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia () Adults: Efficacy was established in four week trials and one Abilify Maintena contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics. Dosing should be initiated atmg/day. Tap the syringe on your hand at least(ten) times (Figure 1). uniform, homogeneous suspension that is opaque and milky-white in color. For patients who have never taken aripiprazole, establish tolerability with The reconstituted ABILIFY MAINTENA is. After tapping, shake the syringe vigorously for at least(ten) seconds, until the medication is uniform (Figure 2) Download the PDF file of the FDA package insert for ABILIFY (aripiprazole), a medication for schizophrenia, bipolar disorder, depression, autism, and Tourette's disorder. Dose adjustments of up tomg/day should occur gradually, at ABILIFY is indicated for the treatment of schizophrenia. If the injection is not performed immediately after reconstitution keep the vial at room temperature and shake the vial vigorously for at leastseconds to re-suspend prior to injection Preparation Prior to Administration. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and It is used to treat schizophreniaa disease with ARIPIPRAZOLE tablets for oral use. The package insert contains information on indications, dosage, warnings, precautions, and adverse reactions Bottles of(NDC) Bottles of 1, (NDC) Aripiprazole tablets, USPmg are available for oral administration as white to off-white, round, slightly biconvex tablets, engraved “ARI” over “20” on one side and “APO” on the other side The recommended dosage range for the treatment of pediatric patients with irritability associated with autistic disorder istomg/day. The efficacy of ABILIFY was established in four week trials in adults and oneweek trial in adolescents (toyears).